期刊
JOURNAL OF CLINICAL MEDICINE
卷 11, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/jcm11216537
关键词
vitamin D receptor; VDR; bone metastasis; vitamin D
资金
- DFG priority program muBONE (SPP2084) project [EB 447/10-1]
- Postdoctoral Research Fellowship of the German Research Foundation (Deutsche Forschungsgemeinschaft) [HO 5109/2-1, HO 5109/2-2]
- Graduate School of Life Sciences, University of Wuerzburg
- Interdisciplinary Center for Clinical Research (IZKF) at the University ofWuerzburg [D-361]
Active vitamin D has direct anti-cancer actions on bone metastases, and vitamin D deficiency is common in these patients.
Active vitamin D (1,25(OH)2D3) is known to exert direct anti-cancer actions on various malignant tissues through binding to the vitamin D receptor (VDR). These effects have been demonstrated in breast, prostate, renal and thyroid cancers, which all have a high propensity to metastasise to bone. In addition, there is evidence that vitamin D catabolism via 24-hydroxylase (CYP24A1) is altered in tumour cells, thus, reducing local active vitamin D levels in cancer cells. The aim of this study was to assess VDR and CYP24A1 expression in various types of bone metastases by using immunohistochemistry. Overall, a high total VDR protein expression was detected in 59% of cases (39/66). There was a non-significant trend of high-grade tumours towards the low nuclear VDR expression (p = 0.07). Notably, patients with further distant metastases had a reduced nuclear VDR expression (p = 0.03). Furthermore, a high CYP24A1 expression was detected in 59% (39/66) of bone metastases. There was a significant positive correlation between nuclear VDR and CYP24A1 expression (p = 0.001). Collectively, the VDR and CYP24A1 were widely expressed in a multitude of bone metastases, pointing to a potential role of vitamin D signalling in cancer progression. This is of high clinical relevance, as vitamin D deficiency is frequent in patients with bone metastases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据